<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573907</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-BEQ-LEVO-007-V.01</org_study_id>
    <nct_id>NCT04573907</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Levothyroxine Sodium Tablets 100 mcg</brief_title>
  <official_title>Comparative Bioavailability Study of Levothyroxine Sodium Tablets 100 mcg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tecnoquimicas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DominguezLab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tecnoquimicas</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the bioequivalence of two levothyroxine&#xD;
      formulations through the estimation of T4 levels in serum samples after baseline correction,&#xD;
      according to Food and Drugs Administration (FDA), World Health Organization (WHO) and&#xD;
      Colombian National Vigilance Institute for Drugs and Food (INVIMA) guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levothyroxine (T4) is used to treat patients with hypothyroidism and may often result in&#xD;
      lifelong therapy. Its physiologically active metabolite is tri-iodothyronine (T3).&#xD;
      Levothyroxine is also endogenously produced in the body. Since small changes in levothyroxine&#xD;
      administration (e.g. change in brand or formulation) can cause significant changes in serum&#xD;
      thyroid stimulating hormone (TSH) concentrations, precise and accurate TSH control is&#xD;
      critical to avoid potential adverse iatrogenic effects. Tecnoquimicas modified its&#xD;
      Levothyroxine tablets formulation in order to comply with new pharmacopeial specifications.&#xD;
      It will then evaluate the impact on drug product performance based on pharmacokinetic (PK)&#xD;
      measures of total serum T4 and total serum T3 of the new formulation of levothyroxine (Test&#xD;
      formulation) relative to the reference formulation from Merck (Reference formulation)&#xD;
&#xD;
      This will be a single-center, open-label, two-period, two-treatment, two-sequence,&#xD;
      randomized, single-dose, crossover study. 80 healthy adults will be randomized to receive a&#xD;
      single dose (6 x 100 mcg tablets = 600 mcg) of the test formulation of levothyroxine and&#xD;
      reference formulation of levothyroxine separately in each treatment period. There will be two&#xD;
      treatment sequences (AB, BA) and a 42 day washout between the two treatment periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(AUC) Area Under the Curve 0-48 for T4</measure>
    <time_frame>[Time Frame: From 0 to 48 hours]</time_frame>
    <description>-30 min., -15 min., 0 hour (h ) pre-dose; 30 min., 1 h, 1.30 h, 2 h, 2.30 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h , 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Cmax) Maximum concentration 0-48 for T4</measure>
    <time_frame>[Time Frame: From 0 to 48 hours]</time_frame>
    <description>-30 min., -15 min., 0 hour ( h) pre-dose; 30 min., 1 h, 1.30 h, 2 h, 2.30 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h , 48 hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Formulation of Levothyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine sodium tablets 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference formulation of Levothyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eutirox 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Levothyroxine 100 mcg</intervention_name>
    <description>Administration of a 600 mcg levothyroxine dose</description>
    <arm_group_label>Test Formulation of Levothyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Eutirox 100 mcg</intervention_name>
    <description>Administration of a 600 mcg levothyroxine dose</description>
    <arm_group_label>Reference formulation of Levothyroxine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Healthy volunteers according to antecedents, clinical evaluation, biochemical tests&#xD;
             and other complimentary tests&#xD;
&#xD;
          -  Sex: both (male and female, homogenously distributed)&#xD;
&#xD;
          -  Age: 18 to 50 years old&#xD;
&#xD;
          -  BMI: 18 to 30 kg/m2&#xD;
&#xD;
          -  Non smokers from at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of liver disease, kidney disease or conditions of psychiatric origin.&#xD;
&#xD;
          -  History of drug or alcohol abuse in the last two years.&#xD;
&#xD;
          -  Ingestion of other drugs the 2 weeks prior to the start of the study.&#xD;
&#xD;
          -  History of seizure disorders, depressive disorders, cardiovascular diseases,&#xD;
             hematological, metabolic, vesicular or other, that the Principal Investigator judges&#xD;
             clinically significant.&#xD;
&#xD;
          -  Abnormal electrocardiogram (EKG).&#xD;
&#xD;
          -  Hypersensitivity to Levothyroxine sodium or to excipients (from formulations to test).&#xD;
&#xD;
          -  Positive HIV test; hepatitis B and C.&#xD;
&#xD;
          -  Positive urine drug dose of abuse.&#xD;
&#xD;
          -  Having participated in another research study in the last 6 months.&#xD;
&#xD;
          -  Having donated blood within the 3 months prior to the start of the study.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory test results.&#xD;
&#xD;
          -  Abnormal results outside the reference values for thyroid function (T3, T4, TSH,&#xD;
             anti-TPO antibodies).&#xD;
&#xD;
          -  Female volunteers who are breastfeeding during the study period.&#xD;
&#xD;
          -  Positive beta-HCG test in female volunteers.&#xD;
&#xD;
          -  Volunteers who must start a scheduled medical or pharmacological treatment outside the&#xD;
             this Protocol.&#xD;
&#xD;
          -  Volunteers who do not maintain the conditions of fasting and food intake in the&#xD;
             pre-established schedules.&#xD;
&#xD;
          -  Volunteers who do not avoid the intake of coffee, tea, grapefruit, cola and / or&#xD;
             alcoholic beverages during the 48 h preceding the study.&#xD;
&#xD;
          -  Volunteers on a special diet in the last 28 days (eg vegetarian diet, etc.).&#xD;
&#xD;
          -  Volunteers with clinically significant allergies to food, medication, etc.&#xD;
&#xD;
          -  Non-cooperative volunteers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DominguezLab</name>
      <address>
        <city>Paraná</city>
        <state>Entre Ríos</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

